[go: up one dir, main page]

MX2022012647A - Composiciones que comprenden tres proteinas de fusion de ospa para uso medico. - Google Patents

Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.

Info

Publication number
MX2022012647A
MX2022012647A MX2022012647A MX2022012647A MX2022012647A MX 2022012647 A MX2022012647 A MX 2022012647A MX 2022012647 A MX2022012647 A MX 2022012647A MX 2022012647 A MX2022012647 A MX 2022012647A MX 2022012647 A MX2022012647 A MX 2022012647A
Authority
MX
Mexico
Prior art keywords
ospa fusion
compositions
fusion proteins
medical use
seq
Prior art date
Application number
MX2022012647A
Other languages
English (en)
Inventor
Urban Lundberg
Kathrin Ute Jansen
Annaliesa Sybil Anderson
Romana Hochreiter
Nicole Bézay
Steven Russell Bailey
Daniel Alfred Scott
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of MX2022012647A publication Critical patent/MX2022012647A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición que comprende la proteína de fusión de OspA de SEQ ID NO: 1 (LipS1D1-S2D1), la proteína de fusión de OspA de SEQ ID NO: 2 (Lip-S4D1-S3hybD1) y la proteína de fusión de OspA de SEQ ID NO:: 3 (Lip-S5D1-S6D1) para usar en una vacuna o para usar en un método para provocar una respuesta inmunitaria en un ser humano contra la enfermedad de Lyme.
MX2022012647A 2020-04-09 2021-04-09 Composiciones que comprenden tres proteinas de fusion de ospa para uso medico. MX2022012647A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20169147 2020-04-09
EP20169148 2020-04-09
EP20169642 2020-04-15
EP20187283 2020-07-22
EP20202816 2020-10-20
US202163152582P 2021-02-23 2021-02-23
PCT/US2021/026599 WO2021207615A1 (en) 2020-04-09 2021-04-09 Compositions comprising three ospa fusion proteins for medical use

Publications (1)

Publication Number Publication Date
MX2022012647A true MX2022012647A (es) 2023-01-16

Family

ID=75581705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012647A MX2022012647A (es) 2020-04-09 2021-04-09 Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.

Country Status (11)

Country Link
US (1) US12514912B2 (es)
EP (1) EP4132950A1 (es)
JP (1) JP2023522170A (es)
KR (1) KR20220167305A (es)
CN (1) CN115698044A (es)
AU (1) AU2021254265A1 (es)
BR (1) BR112022020438A2 (es)
CA (1) CA3174892A1 (es)
IL (1) IL297166A (es)
MX (1) MX2022012647A (es)
WO (1) WO2021207615A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
EP3609911B1 (en) 2017-04-13 2023-07-05 Valneva Austria GmbH Multivalent ospa polypeptides and methods and uses relating thereto
EP4514385A1 (en) 2022-04-25 2025-03-05 Pfizer Inc. Compositions and methods for eliciting an immune response protective against lyme disease
WO2024215721A1 (en) * 2023-04-10 2024-10-17 Modernatx, Inc. Lyme disease vaccines
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP2484375B1 (en) 2006-09-26 2018-05-23 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
JP2013503198A (ja) 2009-08-27 2013-01-31 シナプティック リサーチ，リミテッド ライアビリティ カンパニー 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系
JP6227407B2 (ja) 2010-05-14 2017-11-08 バクスアルタ インコーポレイテッド Ｏｓｐａキメラおよびそのワクチンでの使用法
SI2753352T2 (sl) 2010-09-03 2022-10-28 Valneva Austria Gmbh Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US9925257B2 (en) 2011-09-23 2018-03-27 Forsyth Dental Infirmary For Children Vaccine and therapeutic delivery system
CN103974834B (zh) 2011-12-06 2017-09-05 慕贝尔碳纤维技术有限公司 由纤维增强材料制造的车轮及制造相应车轮的方法
SMT201700607T1 (it) 2011-12-06 2018-01-11 Valneva Austria Gmbh Composti a base di alluminio per uso in agenti terapeutici ed in vaccini
UY34745A (es) * 2012-04-18 2013-11-29 Zoetis Llc Vacunas y procedimientos para tratar la enfermedad de lyme en perros
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
EP3682897A1 (en) * 2012-07-27 2020-07-22 Baxalta GmbH Compositions comprising chimeric ospa molecules and methods of use thereof
KR102460165B1 (ko) * 2014-01-09 2022-10-28 발네바 오스트리아 게엠베하 Ospa의 돌연변이 단편 및 이와 관련된 방법 및 용도
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
US20170212114A1 (en) * 2014-10-07 2017-07-27 The Research Foundation For The State University Of New York Recombinant Borrelia Proteins And Methods Of Use Thereof
JP6947727B2 (ja) 2015-12-10 2021-10-13 ナショナル リサーチ カウンシル オブ カナダ 脂質化肺炎球菌抗原組成物、調製方法及び使用
EP3609911B1 (en) 2017-04-13 2023-07-05 Valneva Austria GmbH Multivalent ospa polypeptides and methods and uses relating thereto
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
MY208001A (en) 2019-05-20 2025-04-03 Valneva Se A subunit vaccine for treatment or prevention of a respiratory tract infection
JP7116256B1 (ja) 2020-04-02 2022-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
EP4133097A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Improved methods of producing a lipidated protein

Also Published As

Publication number Publication date
KR20220167305A (ko) 2022-12-20
US12514912B2 (en) 2026-01-06
BR112022020438A2 (pt) 2022-11-29
AU2021254265A1 (en) 2022-11-03
JP2023522170A (ja) 2023-05-29
IL297166A (en) 2022-12-01
CA3174892A1 (en) 2021-10-14
US20230173051A1 (en) 2023-06-08
WO2021207615A1 (en) 2021-10-14
CN115698044A (zh) 2023-02-03
EP4132950A1 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
MX2022012647A (es) Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
CL2022000094A1 (es) Anticuerpos anti-cd63, conjugados y usos de estos (divisional de la solicitud no. 202002965)
CL2021001162A1 (es) Proteínas de fusión fc il-22 y métodos de uso. (divisional de solicitud 202001944)
ATE318899T1 (de) Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
UA130113C2 (uk) Мутеїн інтерлейкіну-21
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
BR112015013183A2 (pt) proteínas de fusão para uso como aperfeiçoadores imunogênicos para indução de respostas de células t específicas para antígenos
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
UY27840A1 (es) Vacunas
IL189313A (en) Virus-like particles as virus-paramixo vaccines, a method for their preparation and use
BRPI1008692B8 (pt) anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
NO20081043L (no) Vaksine for fisk
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
WO2007098718A8 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
WO2021247715A3 (en) Immunogenic francisella antigens and their use in immunization of fish against francisellosis
Guerra et al. Immunization with a small fragment of the Schmallenberg virus nucleoprotein highly conserved across the Orthobunyaviruses of the Simbu serogroup reduces viremia in SBV challenged IFNAR-/-mice
BR112022021797A2 (pt) Proteínas de fusão para imunoterapia contra o câncer e doenças infecciosas